Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Identifieur interne : 000299 ( France/Analysis ); précédent : 000298; suivant : 000300Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Auteurs : T. Hereng ; M. Lambert [France] ; E. Hachulla ; M. Samor ; S. Dubucquoi ; C. Caron [France] ; D. Launay ; S. Morell-Dubois ; V. Queyrel ; P.-Y. HatronSource :
- Lupus [ 0961-2033 ] ; 2008-01.
English descriptors
- Teeft :
- American college, Anticardiolipin antibodies, Antiphospholipid, Antiphospholipid antibodies, Antiphospholipid antibody, Antiphospholipid syndrome, Aplpositive patients, Aptt, Arthritis rheum, Aspirin, Aspirin intake, Aspirin test, Asymptomatic patients, Autoimmune thrombocytopenia, Cohort, Conventional thrombotic risk factors, Erkan, Erythematosus, Fetal death, Figure curve, Higher risk, Idiopathic phenomenon, Immune thrombocytopenic purpura, Internal medicine, Lupus, Lupus antibodies, Lupus anticoagulants, Lupus erythematosus, Marc lambert, Other diseases, Partial thromboplastin times, Patient subgroups, Primary biliary cirrhosis, Primary prevention, Prospective study, Pulmonary embolism, Rheumatoid arthritis, Standard deviation, Statistical analyses, Syndrome, Systemic lupus erythematosus, Systemic sclerosis, Thromb haemost, Thrombosis, Thrombotic, Thrombotic event, Thrombotic events, University hospital, Venous, Venous thrombosis.
Abstract
One hundred and three consecutive asymptomatic anti-phospholipid (aPL) antibody-positive carriers, taking aspirin (n = 75) or not (n = 28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-phospholipid syndrome (APS) symptoms. All patients positive for anti-cardiolipin antibodies (aCL; >25 UGPL or UMPL) and/or lupus anti-coagulant were followed for a mean of 64 ± 24.7 months. Among aPL-positive patients, 37 had systemic lupus erythematosus (SLE), 20 had prolonged activated partial thromboplastin times, 19 had other connective tissue diseases, 16 had autoimmune thrombocytopenia (AIT), 11 had diverse diseases. Nineteen patients experienced thrombotic event(s) during follow-up. Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P = 0.02). Four of the 10 SLE patients not taking aspirin developed thrombosis compared with 3/27 SLE patients taking aspirin (log-rank test; P = 0.03). Anti-phospholipid -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P = 0.01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients. Lupus (2008) 17, 11—15.
Url:
DOI: 10.1177/0961203307084724
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000720
- to stream Istex, to step Curation: 000720
- to stream Istex, to step Checkpoint: 000896
- to stream Main, to step Merge: 001999
- to stream Main, to step Curation: 001991
- to stream Main, to step Exploration: 001991
- to stream France, to step Extraction: 000299
Links to Exploration step
ISTEX:7D18D17FA4B6162C90F41ABEA7C821453993C739Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients</title><author wicri:is="90%"><name sortKey="Hereng, T" sort="Hereng, T" uniqKey="Hereng T" first="T." last="Hereng">T. Hereng</name></author><author wicri:is="90%"><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M." last="Lambert">M. Lambert</name></author><author wicri:is="90%"><name sortKey="Hachulla, E" sort="Hachulla, E" uniqKey="Hachulla E" first="E." last="Hachulla">E. Hachulla</name></author><author wicri:is="90%"><name sortKey="Samor, M" sort="Samor, M" uniqKey="Samor M" first="M." last="Samor">M. Samor</name></author><author wicri:is="90%"><name sortKey="Dubucquoi, S" sort="Dubucquoi, S" uniqKey="Dubucquoi S" first="S." last="Dubucquoi">S. Dubucquoi</name></author><author wicri:is="90%"><name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name></author><author wicri:is="90%"><name sortKey="Launay, D" sort="Launay, D" uniqKey="Launay D" first="D." last="Launay">D. Launay</name></author><author wicri:is="90%"><name sortKey="Morell Dubois, S" sort="Morell Dubois, S" uniqKey="Morell Dubois S" first="S." last="Morell-Dubois">S. Morell-Dubois</name></author><author wicri:is="90%"><name sortKey="Queyrel, V" sort="Queyrel, V" uniqKey="Queyrel V" first="V." last="Queyrel">V. Queyrel</name></author><author wicri:is="90%"><name sortKey="Hatron, P Y" sort="Hatron, P Y" uniqKey="Hatron P" first="P.-Y." last="Hatron">P.-Y. Hatron</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7D18D17FA4B6162C90F41ABEA7C821453993C739</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1177/0961203307084724</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-641T2Q8M-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000720</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000720</idno><idno type="wicri:Area/Istex/Curation">000720</idno><idno type="wicri:Area/Istex/Checkpoint">000896</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000896</idno><idno type="wicri:doubleKey">0961-2033:2008:Hereng T:influence:of:aspirin</idno><idno type="wicri:Area/Main/Merge">001999</idno><idno type="wicri:Area/Main/Curation">001991</idno><idno type="wicri:Area/Main/Exploration">001991</idno><idno type="wicri:Area/France/Extraction">000299</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients</title><author wicri:is="90%"><name sortKey="Hereng, T" sort="Hereng, T" uniqKey="Hereng T" first="T." last="Hereng">T. Hereng</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M." last="Lambert">M. Lambert</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author><author wicri:is="90%"><name sortKey="Hachulla, E" sort="Hachulla, E" uniqKey="Hachulla E" first="E." last="Hachulla">E. Hachulla</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Samor, M" sort="Samor, M" uniqKey="Samor M" first="M." last="Samor">M. Samor</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Dubucquoi, S" sort="Dubucquoi, S" uniqKey="Dubucquoi S" first="S." last="Dubucquoi">S. Dubucquoi</name><affiliation><wicri:noCountry code="no comma">Immunology Laboratory</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Hemostasis Laboratory, University Hospital of Lille, Faculty of Medicine and Lille University, 59035 Lille Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author wicri:is="90%"><name sortKey="Launay, D" sort="Launay, D" uniqKey="Launay D" first="D." last="Launay">D. Launay</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Morell Dubois, S" sort="Morell Dubois, S" uniqKey="Morell Dubois S" first="S." last="Morell-Dubois">S. Morell-Dubois</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Queyrel, V" sort="Queyrel, V" uniqKey="Queyrel V" first="V." last="Queyrel">V. Queyrel</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Hatron, P Y" sort="Hatron, P Y" uniqKey="Hatron P" first="P.-Y." last="Hatron">P.-Y. Hatron</name><affiliation><wicri:noCountry code="no comma">Department of Internal Medicine</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage UK: London, England</pubPlace><date type="published" when="2008-01">2008-01</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="11">11</biblScope><biblScope unit="page" to="15">15</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>American college</term><term>Anticardiolipin antibodies</term><term>Antiphospholipid</term><term>Antiphospholipid antibodies</term><term>Antiphospholipid antibody</term><term>Antiphospholipid syndrome</term><term>Aplpositive patients</term><term>Aptt</term><term>Arthritis rheum</term><term>Aspirin</term><term>Aspirin intake</term><term>Aspirin test</term><term>Asymptomatic patients</term><term>Autoimmune thrombocytopenia</term><term>Cohort</term><term>Conventional thrombotic risk factors</term><term>Erkan</term><term>Erythematosus</term><term>Fetal death</term><term>Figure curve</term><term>Higher risk</term><term>Idiopathic phenomenon</term><term>Immune thrombocytopenic purpura</term><term>Internal medicine</term><term>Lupus</term><term>Lupus antibodies</term><term>Lupus anticoagulants</term><term>Lupus erythematosus</term><term>Marc lambert</term><term>Other diseases</term><term>Partial thromboplastin times</term><term>Patient subgroups</term><term>Primary biliary cirrhosis</term><term>Primary prevention</term><term>Prospective study</term><term>Pulmonary embolism</term><term>Rheumatoid arthritis</term><term>Standard deviation</term><term>Statistical analyses</term><term>Syndrome</term><term>Systemic lupus erythematosus</term><term>Systemic sclerosis</term><term>Thromb haemost</term><term>Thrombosis</term><term>Thrombotic</term><term>Thrombotic event</term><term>Thrombotic events</term><term>University hospital</term><term>Venous</term><term>Venous thrombosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One hundred and three consecutive asymptomatic anti-phospholipid (aPL) antibody-positive carriers, taking aspirin (n = 75) or not (n = 28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-phospholipid syndrome (APS) symptoms. All patients positive for anti-cardiolipin antibodies (aCL; >25 UGPL or UMPL) and/or lupus anti-coagulant were followed for a mean of 64 ± 24.7 months. Among aPL-positive patients, 37 had systemic lupus erythematosus (SLE), 20 had prolonged activated partial thromboplastin times, 19 had other connective tissue diseases, 16 had autoimmune thrombocytopenia (AIT), 11 had diverse diseases. Nineteen patients experienced thrombotic event(s) during follow-up. Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P = 0.02). Four of the 10 SLE patients not taking aspirin developed thrombosis compared with 3/27 SLE patients taking aspirin (log-rank test; P = 0.03). Anti-phospholipid -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P = 0.01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients. Lupus (2008) 17, 11—15.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li></settlement></list><tree><noCountry><name sortKey="Dubucquoi, S" sort="Dubucquoi, S" uniqKey="Dubucquoi S" first="S." last="Dubucquoi">S. Dubucquoi</name><name sortKey="Hachulla, E" sort="Hachulla, E" uniqKey="Hachulla E" first="E." last="Hachulla">E. Hachulla</name><name sortKey="Hatron, P Y" sort="Hatron, P Y" uniqKey="Hatron P" first="P.-Y." last="Hatron">P.-Y. Hatron</name><name sortKey="Hereng, T" sort="Hereng, T" uniqKey="Hereng T" first="T." last="Hereng">T. Hereng</name><name sortKey="Launay, D" sort="Launay, D" uniqKey="Launay D" first="D." last="Launay">D. Launay</name><name sortKey="Morell Dubois, S" sort="Morell Dubois, S" uniqKey="Morell Dubois S" first="S." last="Morell-Dubois">S. Morell-Dubois</name><name sortKey="Queyrel, V" sort="Queyrel, V" uniqKey="Queyrel V" first="V." last="Queyrel">V. Queyrel</name><name sortKey="Samor, M" sort="Samor, M" uniqKey="Samor M" first="M." last="Samor">M. Samor</name></noCountry><country name="France"><noRegion><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M." last="Lambert">M. Lambert</name></noRegion><name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000299 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:7D18D17FA4B6162C90F41ABEA7C821453993C739
|texte= Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
}}
| This area was generated with Dilib version V0.6.33. |  |